Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin DeJesus

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|October 4, 2008
Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick, Jacob Lalezari, James Goodrich, et al.
HIV Clinical Trials|June 21, 2011
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patientsDaniel J Skiest, Calvin Cohen, Karam Mounzer, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
HIV Clinical Trials|June 27, 2006
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle, Schlomo Staszweski, Bonaventura Clotet, et al.
HIV Clinical Trials|May 18, 2012
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study resultsMichael J Kozal, Sergio Lupo, Edwin DeJesus, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Eric Lawitz, Gary Matusow, Edwin DeJesus, et al.
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|October 4, 2008
Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick, Jacob Lalezari, James Goodrich, et al.
HIV Clinical Trials|June 21, 2011
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patientsDaniel J Skiest, Calvin Cohen, Karam Mounzer, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
HIV Clinical Trials|June 27, 2006
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle, Schlomo Staszweski, Bonaventura Clotet, et al.
HIV Clinical Trials|May 18, 2012
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study resultsMichael J Kozal, Sergio Lupo, Edwin DeJesus, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Eric Lawitz, Gary Matusow, Edwin DeJesus, et al.
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Pageof 16